AATec Medical starts collaboration with the German Federal Agency for Disruptive Innovation SPRIND for alpha-1 antitrypsin
Project for the preclinical development of ATL-105, a recombinant alpha-1 antitrypsin (AAT)-based drug platform for the treatment of inflammatory diseases, viral infections, and ra